Weighted proportions of participants reporting AEs for those using prescription drugs, NHPs or both, by pharmacy and province
| Pharmacy | Participants reporting AE (ni) | Prescription drug use AEs (np) (pp) | NHP use only AEs (nn) (pn) | Concurrent use AEs (nc) (pc) | |
|---|---|---|---|---|---|
| AB01 | 5 | 0 (0.0%) | 0 (0.0%) | 5 (6.9%) | |
| AB02 | 8 | 1 (3.0%) | 1 (11.1%) | 6 (8.0%) | |
| AB03 | 10 | 2 (6.3%) | 0 (0.0%) | 8 (12.5%) | |
| AB04 | 19 | 1 (1.4%) | 0 (0.0%) | 8 (8.1%) | |
| AB05 | 3 | 0 (0.0%) | 0 (0.0%) | 3 (60.0%) | |
| AB06 | 5 | 0 (0.0%) | 0 (0.0%) | 5 (4.7%) | |
| AB07 | 3 | 1 (6.3%) | 0 (0.0%) | 2 (8.7%) | |
| Alberta total | 53 | 5 (1.9%) (95% CI 0.8 to 4.4) | 1 (3.0%) (95% CI 0.4 to 18.6) | 47 (8.3%) (95% CI 6.3 to 10.8) | |
| BC01 | 0 | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |
| BC02 | 1 | 0 (0.0%) | 0 (0.0%) | 1 (4.0%) | |
| BC03 | 0 | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |
| British Columbia total | 1 | 0 (0.0%) | 0 (0.0%) | 1 (1.1%) (95% CI 0.2 to 7.5) | |
| Western Canada total | 54 | 5 (1.2%) (95% CI 0.51 to 2.9) | 1 (2.7%) (95% CI 0.4 to 16.9) | 48 (7.3%) (95% CI 5.6 to 9.6) |
AEs, adverse events; NHPs, natural health products.